We are live on ! Find out more
WST icon

West Pharmaceutical

573 hedge funds and large institutions have $18.8B invested in West Pharmaceutical in 2020 Q3 according to their latest regulatory filings, with 101 funds opening new positions, 199 increasing their positions, 210 reducing their positions, and 48 closing their positions.

New
Increased
Maintained
Reduced
Closed

191% more call options, than puts

Call options by funds: $20M | Put options by funds: $6.87M

110% more first-time investments, than exits

New positions opened: 101 | Existing positions closed: 48

19% more capital invested

Capital invested by funds: $15.8B → $18.8B (+$2.98B)

10% more funds holding

Funds holding: 523573 (+50)

0% more funds holding in top 10

Funds holding in top 10: 99 (0)

5% less repeat investments, than reductions

Existing positions increased: 199 | Existing positions reduced: 210

1.26% less ownership

Funds ownership: 94.11%92.85% (-1.3%)

Holders
573
Holders Change
+50
Holders Change %
+9.56%
% of All Funds
11.56%
Holding in Top 10
9
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.18%
New
101
Increased
199
Reduced
210
Closed
48
Calls
$20M
Puts
$6.87M
Net Calls
+$13.1M
Net Calls Change
+$2.64M
Name Holding Trade Value Shares
Change
Change in
Stake
WCM
301
Weld Capital Management
New York
$1.25M -$181K -684 -13%
DZ Bank
302
DZ Bank
Germany
$1.24M +$1.06M +4,016 +830%
OPPTF
303
OPSEU Pension Plan Trust Fund
Ontario, Canada
$1.19M +$8.47K +32 +0.8%
KRS
304
Kentucky Retirement Systems
Kentucky
$1.19M +$56.1K +212 +5%
BCV
305
Banque Cantonale Vaudoise
Switzerland
$1.18M -$52.9K -200 -4%
FA
306
FDx Advisors
Illinois
$1.17M +$695K +2,626 +162%
Connor, Clark & Lunn Investment Management (CC&L)
307
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.11M +$283K +1,068 +36%
Wealthfront Advisers
308
Wealthfront Advisers
California
$1.11M +$180K +682 +20%
Cambridge Investment Research Advisors
309
Cambridge Investment Research Advisors
Iowa
$1.09M +$108K +408 +11%
BAMF
310
BI Asset Management Fondsmaeglerselskab
Denmark
$1.09M +$475K +1,794 +82%
ECM
311
ExodusPoint Capital Management
New York
$1.08M +$1.04M +3,931 New
SCA
312
Summit Creek Advisors
Minnesota
$1.07M
EHC
313
Everett Harris & Co
California
$1.07M
CFGS
314
Concourse Financial Group Securities
Alabama
$1.07M -$111K -421 -10%
VWM
315
Venturi Wealth Management
Texas
$1.04M +$329K +1,244 +49%
APA
316
American Portfolios Advisors
New York
$1.04M +$938K +3,545 +1,541%
Rockefeller Capital Management
317
Rockefeller Capital Management
New York
$1.02M +$48.2K +182 +5%
BOC
318
Barbara Oil Co
Illinois
$1.02M
LSERS
319
Louisiana State Employees Retirement System
Louisiana
$1.02M +$132K +500 +16%
DCM
320
Dupont Capital Management
Delaware
$999K -$2.85M -10,788 -75%
APWM
321
Atlas Private Wealth Management
New York
$997K
DTL
322
Dynamic Technology Lab
Singapore
$992K +$955K +3,609 New
TC
323
Toews Corporation
New Jersey
$990K +$953K +3,600 New
Daiwa Securities Group
324
Daiwa Securities Group
Japan
$974K +$130K +492 +16%
MCM
325
MAI Capital Management
Ohio
$966K -$239K -905 -20%

WST Hedge Fund Activity: Q3 2020 in Review

573 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q3 2020, worth a combined $18.8B — up 19% from $15.8B a quarter earlier.

Buyers outnumbered sellers: 101 funds opened new WST positions and 48 closed out — a net gain of 53 holders — while 199 added to existing stakes and 210 trimmed.

The largest buyer was Invesco, adding an estimated $123M. The largest seller was T. Rowe Price Associates, cutting an estimated $223M.

  • 573 institutional investors held West Pharmaceutical (WST) as of Q3 2020, up from 523 in Q2 2020.
  • Funds reported $18.8B of West Pharmaceutical stock for Q3 2020, up 19% quarter-over-quarter.
  • 101 funds opened new West Pharmaceutical positions in Q3 2020 and 48 closed out, a net change of +53 holders.
  • The largest West Pharmaceutical buyer in Q3 2020 was Invesco, an estimated $123M added.
  • The largest West Pharmaceutical seller in Q3 2020 was T. Rowe Price Associates, an estimated $223M sold.

Based on aggregated 13F filings for Q3 2020.